| abstract |
The invention relates to novel liquid pharmaceutical compositions of adalimumab which include adalimumab or a biosimilar agent thereof, a citrate buffer agent / system such as sodium citrate / citric acid, and a sugar stabilizer such as trehalose. Such a combination of constituents provides formulations with a stability (e.g., by storage or exposures to loads) that are comparable to or improved from those known in the art and with fewer constituents. Such advances will promote the availability of adalimumab treatments at a lower cost and extend the shelf life of pre-filled dispensing devices (eg pre-filled syringes), thus reducing unnecessary waste of the drug. |